Uptrend on the daily chart: above its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Oct 8 · above the Ichimoku cloud · RSI 55 · MACD below its signal
None of the 29 investors followed here reported a position in MIR.V in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MIR.V trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for MIR.V.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | -14.3 | 0.0 | 16.7 | -14.3 | 16.7 | 0.0 | -7.1 | −7.1% | ||
| 2025 | 40.0 | -21.4 | -18.2 | 11.1 | -10.0 | -11.1 | 0.0 | 0.0 | 25.0 | -20.0 | 0.0 | -12.5 | −30.0% |
| 2024 | -18.2 | 11.1 | -10.0 | 0.0 | 0.0 | -11.1 | 25.0 | -10.0 | -11.1 | 0.0 | 12.5 | 11.1 | −9.1% |
| 2023 | 50.0 | 16.7 | -14.3 | -25.0 | 0.0 | 0.0 | 0.0 | 11.1 | -10.0 | 0.0 | 0.0 | 22.2 | +37.5% |
| 2022 | -15.0 | -17.6 | 0.0 | -21.4 | 0.0 | 18.2 | 0.0 | -15.4 | -18.2 | -22.2 | 0.0 | 14.3 | −60.0% |
| 2021 | 28.0 | -12.5 | -14.3 | -20.8 | -5.3 | -22.2 | -14.3 | 33.3 | -6.2 | -13.3 | 0.0 | 53.8 | −20.0% |
| 2020 | 200.0 | -33.3 | 0.0 | 1250.0 | 100.0 | -29.6 | 10.5 | -19.0 | -11.8 | -6.7 | 3.6 | -13.8 | +2400.0% |
| 2019 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100.0 | -50.0 | 0.0 | 0.0 | 100.0 | 0.0 | -50.0 | 0.0% |
| 2018 | 50.0 | -33.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -50.0 | 0.0 | −50.0% |
| 2017 | 0.0 | 0.0 | 33.3 | -25.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -33.3 | −33.3% |
| 2016 | 0.0 | -20.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 25.0 | -40.0 | 0.0 | 0.0 | −40.0% |
| 2015 | 20.0 | -16.7 | 0.0 | -20.0 | 25.0 | -20.0 | 0.0 | 0.0 | 0.0 | 25.0 | 0.0 | 0.0 | 0.0% |
| 2014 | 116.7 | -30.8 | 11.1 | -10.0 | -11.1 | -12.5 | -14.3 | 0.0 | 16.7 | -14.3 | 0.0 | -16.7 | −16.7% |
| 2013 | 0.0 | 0.0 | 20.0 | 0.0 | 0.0 | -16.7 | 0.0 | 0.0 | 0.0 | 0.0 | 20.0 | 0.0 | +20.0% |
| 2012 | 33.3 | 0.0 | -25.0 | 33.3 | 0.0 | 50.0 | -16.7 | -20.0 | 25.0 | -20.0 | 50.0 | -16.7 | +66.7% |
| 2011 | 0.0 | 0.0 | -25.0 | 33.3 | 0.0 | 0.0 | 0.0 | 0.0 | -25.0 | 0.0 | 0.0 | 0.0 | −25.0% |
| 2010 | -16.7 | 20.0 | -16.7 | -20.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −33.3% |
| 2009 | 16.7 | -28.6 | 20.0 | 16.7 | 28.6 | -22.2 | 0.0 | -14.3 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0% |
| 2008 | -44.4 | 10.0 | -21.2 | -19.2 | -4.8 | -30.0 | 35.7 | -15.8 | -25.0 | -25.0 | -22.2 | -14.3 | −88.9% |
| 2007 | -12.0 | 0.0 | -18.2 | -11.1 | -12.5 | 0.0 | -14.3 | -16.7 | 30.0 | 15.4 | 260.0 | 0.0 | +116.0% |
No analyst coverage for this instrument.
MedMira Inc., a biotechnology company, researches, develops, manufactures, and sells rapid diagnostics and technology platforms in North America, Europe, and internationally. The company offers Reveal HIV, a test that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product for preliminary screening of HIV and hepatitis. It also provides the Miriad RVF toolkit, which facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
No recent headlines.